Aims and Objectives: To score and compare micronucleus (MN) in the whole spectrum of cervical lesions including normal, inflammatory, abnormal squamous cell of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL) and invasive cancer (IC) and to evaluate the role of MN as a biomarker in different pre-neoplastic and neoplastic lesions. Materials and Methods: A total of 224 slides, comprised of normal (40), inflammatory (40), ASC-US (30), LSIL (38), HSIL (30) and IC (46), were studied. All the cases of HSIL, IC and ASC-US had histopathology. The LSIL, normal and inflammatory smears were again reviewed by 2 experienced cytopathologists independently. Two observers separately and independently counted the number of micronucleated cells per 1,000 of epithelial cells in oil immersion magnification (×100 objective) which was expressed as MN score per 1,000 cells. Results: The mean MN scores ± SD in normal, inflammatory, ASC-US, LSIL, HSIL and IC cases of cervical lesions were 1.02 ± 1.59, 0.4250 ± 0.71208, 2.87 ± 2.21, 4.7368 ± 5.62179, 21.30 ± 17.18 and 18.50 ± 9.54, respectively. MN scores of IC and HSIL were significantly high compared to the normal (p < 0.000), the inflammatory (p < 0.000), the ASC-US (p < 0.000) and to the LSIL (p < 0.000) group (analysis of variance test). LSIL showed significant difference with the normal (p = 0.043), the inflammatory (p = 0.019), the HSIL (p < 0.000) and the IC (p < 0.000) group but not with the ASC-US (p = 0.342) group. Conclusions: MN scoring on the epithelial cells of cervix could be used as a biomarker in cancer screening. This is an easy, simple, reliable, reproducible and objective test which can be performed on routinely stained smears.

Keywords:
Cervical smear, Cervix, Micronucleus, Screening
1.
Fenech M, Holland N, Chang WP, Zeiger E, Bonassi S: The human micronucleus project: an international collaborative study on the use of the micronucleus technique for measuring DNA damage in humans. Mutat Res 1999;428:271–283.
2.
Fenech M, Morley AA: Cytokinesis-block micronucleus method in human lymphocytes: effect of in vivo ageing and low-dose X-irradiation. Mutat Res 1986;161:193–198.
3.
Chang WP, Hwang BF, Wang D, Wang JD: Cytogenetic effect of chronic low-dose, low-dose-rate gamma-radiation in residents of irradiated buildings. Lancet 1997;350:330–333.
4.
Aposhian HV, Arroyo A, Cebrian ME, et al: DMPS-arsenic challenge test. I. Increased urinary excretion of monomethylarsonic acid in humans given dimercaptopropane sulfonate. J Pharmacol Exp Ther 1997;282:192–200.
5.
Ozkul Y, Donmez H, Erenmemisoglu A, Demirtas H, Imamoglu N: Induction of micronuclei by smokeless tobacco on buccal mucosa cells of habitual users. Mutagenesis 1997;12:285–287.
6.
Fenech M: Chromosomal biomarkers of genomic instability relevant to cancer. Drug Discov Today 2002;7:1128–1137.
7.
Martino-Roth MG, Viegas J, Roth DM: Occupational genotoxicity risk evaluation through the comet assay and the micronucleus test. Genet Mol Res 2003;2:410–417.
8.
Goud KI, Hasan Q, Balakrishna N, Rao KP, Ahuja YR: Genotoxicity evaluation of individuals working with photocopying machines. Mutat Res 2004;563:151–158.
9.
Bloching M, Hofmann A, Lautenschlager C, Berghaus A, Grummt T: Exfoliative cytology of normal buccal mucosa to predict the relative risk of cancer in the upper aerodigestive tract using the MN-assay. Oral Oncol 2000;36:550–555.
10.
Machado-Santelli GM, Cerqueira EM, Oliveira CT, Pereira CA: Biomonitoring of nurses handling antineoplastic drugs. Mutat Res 1994;322:203–208.
11.
Burgaz S, Karahalil B, Bayrak P, et al: Urinary cyclophosphamide excretion and micronuclei frequencies in peripheral lymphocytes and in exfoliated buccal epithelial cells of nurses handling antineoplastics. Mutat Res 1999;439:97–104.
12.
Cavallo D, Ursini CL, Perniconi B, et al: Evaluation of genotoxic effects induced by exposure to antineoplastic drugs in lymphocytes and exfoliated buccal cells of oncology nurses and pharmacy employees. Mutat Res 2005;587:45–51.
13.
Karahalil B, Karakaya AE, Burgaz S: The micronucleus assay in exfoliated buccal cells: application to occupational exposure to polycyclic aromatic hydrocarbons. Mutat Res 1999;442:29–35.
14.
Iarmarcovai G, Ceppi M, Botta A, Orsiere T, Bonassi S: Micronuclei frequency in peripheral blood lymphocytes of cancer patients: a meta-analysis. Mutat Res 2008;659:274–283.
15.
Holland N, Bolognesi C, Kirsch-Volders M, et al: The micronucleus assay in human buccal cells as a tool for biomonitoring DNA damage: the HUMN project perspective on current status and knowledge gaps. Mutat Res 2008;659:93–108.
16.
Delfino V, Casartelli G, Garzoglio B, et al: Micronuclei and p53 accumulation in preneoplastic and malignant lesions in the head and neck. Mutagenesis 2002;17:73–77.
17.
Casartelli G, Bonatti S, De Ferrari M, et al: Micronucleus frequencies in exfoliated buccal cells in normal mucosa, precancerous lesions and squamous cell carcinoma. Anal Quant Cytol Histol 2000;22:486–492.
18.
Desai SS, Ghaisas SD, Jakhi SD, Bhide SV: Cytogenetic damage in exfoliated oral mucosal cells and circulating lymphocytes of patients suffering from precancerous oral lesions. Cancer Lett 1996;109:9–14.
19.
Rajeswari N, Ahuja YR, Malini U, et al: Risk assessment in first degree female relatives of breast cancer patients using the alkaline Comet assay. Carcinogenesis 2000;21:557–561.
20.
Saran R, Tiwari RK, Reddy PP, Ahuja YR: Risk assessment of oral cancer in patients with pre-cancerous states of the oral cavity using micronucleus test and challenge assay. Oral Oncol 2008;44:354–360.
21.
Tolbert PE, Shy CM, Allen JW: Micronuclei and other nuclear anomalies in buccal smears: methods development. Mutat Res 1992;271:69–77.
22.
Nersesyan AK: Possible role of the micronucleus assay in diagnostics and secondary prevention of cervix cancer: a minireview. Cytology Genet 2007;41:317–318.
23.
Guzma’n P, Sotelo-Regil RC, Mohar A, Gonsebat ME: Positive correlation between the frequency of micronucleated cells and dysplasia in Papanicolaou smears. Environ Mol Mutagen 2003;41:339–343.
24.
Andrew JO, Rita S, Gilberto SL, et al: Tetraploidy and chromosomal instability are early events during cervical carcinogenesis. Carcinogenesis 2006;27:337–343.
25.
Garcia BP, Hoegel J, Varga D, et al: Scoring variability in human micronuclei binucleated lymphocytes in a case control study. Mutagenesis 2006;21:191–197.
26.
Liao SY, Stanbridge EJ: Expression of the MN antigen in cervical Papanicolaou smears is an early diagnostic biomarker of cervical dysplasia. Cancer Epidemiol Biomarkers Prev 1996;5:549–557.
27.
Milde-Langosch K, Riethforf S, Loning T: Association of human papillomavirus infection with carcinoma of the cervix uteri and its precursor lesions: theoretical and practical implications. Virchows Arch 2000;437:227–233.
28.
Leal-Garza CH, Cerda-Flores RM, Leal-Elizondo E, Cortes-Gutierrez EI: Micronuclei in cervical smears and peripheral blood lymphocytes from women with and without cervical uterine cancer. Mutat Res 2002;515:57–62.
29.
Widel M, Kolosza Z, Jedrus S, Lukaszczyk B, Raczek-Zwierzycka K, Swierniak A: Micronucleus assay in vivo provides significant prognostic information in human cervical carcinoma; the updated analysis. Int J Radiat Biol 2001;77:631–636.
30.
Heselmeyer-Haddad K, Janz V, Castle PE, et al: Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia. Am J Pathol 2003;163:1405–1416.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.